Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

Abstract:

BACKGROUND:The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM:To compare the long-term outcome of PAI vs. PEI for treating small HCC. METHODS:From July 1998 to July 2004, 125 patients with small HCC were enrolled. Seventy patients receiving PAI and 55 patients receiving PEI were enrolled. There were no significant differences in the clinical characteristics between the two groups. Tumour recurrence and survival rates were assessed. RESULTS:Mean follow-up time was 43 months. The local recurrence rate and new tumour recurrence rate were similar between the PAI and PEI groups. The PAI group had significantly better survival than the PEI group (P = 0.027). Multivariate analysis revealed that PAI was the significant factor associated with overall survival [PAI vs. PEI, RR: 0.639, 95% CI: (0.419-1.975), P = 0.038]. The treatment sessions required to achieve complete tumour necrosis were significantly fewer in the PAI group than in the PEI group (2.4 +/- 1.0 vs. 2.9 +/- 1.3, P = 0.018). CONCLUSION:Percutaneous acetic acid injection required fewer treatment sessions than PEI and provided better survival after long-term follow-up.

journal_name

Aliment Pharmacol Ther

authors

Tsai WL,Cheng JS,Lai KH,Lin CP,Lo GH,Hsu PI,Yu HC,Lin CK,Chan HH,Chen WC,Chen TA,Li WL,Liang HL

doi

10.1111/j.1365-2036.2008.03702.x

subject

Has Abstract

pub_date

2008-08-01 00:00:00

pages

304-11

issue

3

eissn

0269-2813

issn

1365-2036

journal_volume

28

pub_type

杂志文章
  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract:BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12202

    authors: Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期:2013-03-01 00:00:00

  • Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome.

    abstract:AIM:To study the effect of prokinetic treatment with cisapride in patients with constipation-predominant irritable bowel syndrome. PATIENTS AND METHODS:Ninety-six patients were randomly assigned to treatment with either cisapride 5 mg three times daily or placebo three times daily for a period of 12 weeks. The dosage ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1997.133311000.x

    authors: Schütze K,Brandstätter G,Dragosics B,Judmaier G,Hentschel E

    更新日期:1997-04-01 00:00:00

  • Plasma antioxidant levels in chronic cholestatic liver diseases.

    abstract:BACKGROUND:[corrected] A predictable consequence of cholestasis is malabsorption of fat-soluble factors, (vitamins A, D, E, K) and other free radical scavengers, such as carotenoids. It has been suggested that oxygen-derived free radicals may be involved in the pathogenesis of chronic liver damage. AIMS:(i) To evaluat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00729.x

    authors: Floreani A,Baragiotta A,Martines D,Naccarato R,D'odorico A

    更新日期:2000-03-01 00:00:00

  • Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

    abstract:BACKGROUND:Some of mucosal defensive agents have anti-Helicobacter pylori activities. However, their effectiveness in eradicating H. pylori infection has not been evaluated. AIM:To assess the additive effect of mucosal defensive agents in eradication regimens using statistical analysis. METHODS:Pertinent studies were...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.2000.00692.x

    authors: Hojo M,Miwa H,Kikuchi S,Sato N

    更新日期:2000-02-01 00:00:00

  • Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.

    abstract:BACKGROUND:Serum vitamin D levels are associated with bone complications in patients with primary biliary cirrhosis (PBC). Increasing evidence suggests a nonskeletal role of vitamin D in various autoimmune and liver diseases. AIM:To investigate the clinical relevance of vitamin D levels in PBC, especially their associ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13244

    authors: Guo GY,Shi YQ,Wang L,Ren X,Han ZY,Guo CC,Cui LN,Wang JB,Zhu J,Wang N,Zhang J,Cai Y,Han Y,Zhou XM,Fan DM

    更新日期:2015-07-01 00:00:00

  • Review article: cytomegalovirus and inflammatory bowel disease.

    abstract:BACKGROUND:The association between ulcerative colitis and cytomegalovirus (CMV) has been recognised for over 50 years; and the role of CMV in ulcerative colitis in general, and steroid resistance in particular, remains a topic of ongoing controversy. The outcome for patients with CMV reactivation appears worse than tha...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.13124

    authors: Sager K,Alam S,Bond A,Chinnappan L,Probert CS

    更新日期:2015-04-01 00:00:00

  • Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.

    abstract:BACKGROUND:Patient-reported outcome (PRO) measures historically used in inflammatory bowel disease have been considered inadequate to support future drug labelling claims by regulatory agencies. AIMS:To develop PRO tools for use in Crohn's disease (CD) and ulcerative colitis (UC) following guidance issued by the US FD...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15726

    authors: Dulai PS,Jairath V,Khanna R,Ma C,McCarrier KP,Martin ML,Parker CE,Morris J,Feagan BG,Sandborn WJ

    更新日期:2020-06-01 00:00:00

  • Citric acid-enhanced Helicobacter pylori urease activity in vivo is unrelated to gastric emptying.

    abstract:BACKGROUND:In a previous study, the use of a citric acid test meal produced a rapid dose-dependent increase in urease activity that was significantly greater than that resulting from a pudding meal, ascorbic acid or sodium citrate. The mechanism was hypothesized to be related to the ability of citric acid to delay gast...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01096.x

    authors: Shiotani A,Saeed A,Yamaoka Y,Osato MS,Klein PD,Graham DY

    更新日期:2001-11-01 00:00:00

  • Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer.

    abstract:BACKGROUND:Radiotherapy is an established treatment modality for prostate cancer; however, up to a third of patients develops a radiation-induced proctopathy. AIM:To assess the effect of topical beclomethasone dipropionate (BDP) in the prevention of radiation-induced proctopathy in patients undergoing radiotherapy for...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2011.04780.x

    authors: Fuccio L,Guido A,Laterza L,Eusebi LH,Busutti L,Bunkheila F,Barbieri E,Bazzoli F

    更新日期:2011-09-01 00:00:00

  • Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

    abstract:BACKGROUND:Antibiotic resistance and duration of therapy influence the success of proton-pump inhibitor-containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. AIM:To examine the success of a 7-day rabeprazole-clarithromycin-amoxicillin therapy in the study p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02755.x

    authors: Cardenas VM,Graham DY,El-Zimaity HM,Opekun AR,Campos A,Chavez A,Guerrero L

    更新日期:2006-01-15 00:00:00

  • Effects of ranitidine on maternal gastric juice and neonates when administered prior to caesarean section.

    abstract::Ranitidine hydrochloride, a histamine H2-receptor antagonist, was intravenously administered to 61 pregnant women at a dose of 50 mg as premedication for caesarean section; its effects on gastric secretion were studied in the mother and the newborn. The volume of the maternal gastric juice collected immediately after ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1991.tb00033.x

    authors: Ikenoue T,Iito J,Matsuda Y,Hokanishi H

    更新日期:1991-06-01 00:00:00

  • Capsule endoscopy - comparison of two strategies of bowel preparation.

    abstract:BACKGROUND:Capsule endoscopy can identify lesions of the small bowel that cannot be detected by other techniques. In addition to patient safety, quality of care and cost-efficiency, good preparation is an important factor for good visualization. AIM:To evaluate the efficacy of oral sodium phosphate preparation. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2005.02647.x

    authors: Niv Y,Niv G,Wiser K,Demarco DC

    更新日期:2005-11-15 00:00:00

  • Review article: visceral hypersensitivity.

    abstract::Visceral hypersensitivity is highly prevalent in all functional bowel disorders. Most also demonstrate wider patterns of somatic referral of intestinal pain or discomfort. This hypersensitivity may explain the symptoms as the sensitive gut can be more easily provoked by normal or abnormal motor events in the gut. Visc...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01447.x

    authors: Mertz H

    更新日期:2003-03-01 00:00:00

  • Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.

    abstract:BACKGROUND:Controversy exists on how to measure patient-reported outcomes in irritable bowel syndrome (IBS) clinical trials effectively. Pain numeric rating scales (NRS) are widely used in the non-IBS pain literature. The Food and Drug Administration has proposed using the NRS in IBS. AIM:To test the psychometrics of ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04144.x

    authors: Spiegel B,Bolus R,Harris LA,Lucak S,Naliboff B,Esrailian E,Chey WD,Lembo A,Karsan H,Tillisch K,Talley J,Mayer E,Chang L

    更新日期:2009-12-01 00:00:00

  • Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders.

    abstract:BACKGROUND:Fructose malabsorption, lactose malabsorption and an early rise in breath hydrogen after lactulose (ERBHAL) may play roles in induction of symptoms in gastrointestinal conditions. AIM:To compare prevalence and interactions of fructose malabsorption, lactose malabsorption and ERBHAL among healthy subjects an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04018.x

    authors: Barrett JS,Irving PM,Shepherd SJ,Muir JG,Gibson PR

    更新日期:2009-07-01 00:00:00

  • Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.

    abstract::In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o.m. and 91 cimetidine 800 mg nocte for 2 or, if then not healed, 4 weeks. After 2 weeks the healing rates on an intention-to-treat basis were: for omeprazole 62% and for cimetidine 33% (P less than 0.001), an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00193.x

    authors: Crowe JP,Wilkinson SP,Bate CM,Willoughby CP,Peers EM,Richardson PD

    更新日期:1989-02-01 00:00:00

  • Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels.

    abstract:BACKGROUND:Omeprazole maintenance therapy for gastro-oesophageal reflux disease (GERD) has been associated with an increased incidence of atrophic gastritis in H. pylori-infected patients and with a decreased absorption of protein-bound, but not of unbound cobalamin. AIM:: To test the hypothesis that the combination o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00616.x

    authors: Schenk BE,Kuipers EJ,Klinkenberg-Knol EC,Bloemena EC,Sandell M,Nelis GF,Snel P,Festen HP,Meuwissen SG

    更新日期:1999-10-01 00:00:00

  • Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors.

    abstract:BACKGROUND:Bodybuilding supplements can cause a profound cholestatic syndrome. AIM:To describe the drug-Induced liver injury network's experience with liver injury due to bodybuilding supplements. METHODS:Liver injury pattern, severity and outcomes, potential genetic associations, and exposure to anabolic steroids by...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15211

    authors: Stolz A,Navarro V,Hayashi PH,Fontana RJ,Barnhart HX,Gu J,Chalasani NP,Vega MM,Bonkovsky HL,Seeff LB,Serrano J,Avula B,Khan IA,Cirulli ET,Kleiner DE,Hoofnagle JH,DILIN Investigators.

    更新日期:2019-05-01 00:00:00

  • Review article: Helicobacter pylori and nonulcer dyspepsia.

    abstract::Although up to 50% of patients diagnosed with nonulcer dyspepsia (NUD) have Helicobacter pylori infection and underlying chronic gastritis, it remains controversial whether any causal relationship exists. The results of worldwide epidemiological studies have been unconvincing. No clear-cut link has been documented bet...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.0160s1058.x

    authors: Talley NJ,Quan C

    更新日期:2002-03-01 00:00:00

  • Effects on the rat oxyntic mucosa of the histamine2-antagonist loxtidine and the H+, K(+)-ATPase inhibitor omeprazole.

    abstract::The present study examined whether histamine could affect the growth of the enterochromaffin-like (ECL) cell and the parietal cell. The effects of the unsurmountable histamine H2-receptor antagonist loxtidine (80 mg/kg) and the H+, K(+)-ATPase inhibitor omeprazole (100 mumol/kg) were compared in female Sprague-Dawley ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1992.tb00055.x

    authors: Brenna E,Waldum HL,Sandvik AK,Schulze Søgnen B,Kristensen A

    更新日期:1992-06-01 00:00:00

  • Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

    abstract:BACKGROUND:Infection is the most common cause of mortality in end-stage liver disease (ESLD). The impact of obesity on infection risk in ESLD is not established. AIM:To characterise the impact of obesity on infection risk in ESLD. METHODS:We evaluated the association between infection and obesity in patients with ESL...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13426

    authors: Sundaram V,Kaung A,Rajaram A,Lu SC,Tran TT,Nissen NN,Klein AS,Jalan R,Charlton MR,Jeon CY

    更新日期:2015-12-01 00:00:00

  • Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.

    abstract::To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02817.x

    authors: Malfertheiner P,Fass R,Quigley EM,Modlin IM,Malagelada JR,Moss SF,Holtmann G,Goh KL,Katelaris P,Stanghellini V,Talley NJ,Tytgat GN,Wright NA

    更新日期:2006-03-15 00:00:00

  • Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study.

    abstract:BACKGROUND:After ileocaecal resection for Crohn's disease (CD), inflammatory lesions frequently recur on the anastomosis and/or on the neo-terminal ileum. AIM:To identify predictors of early post-operative endoscopic recurrence. METHODS:From September 2010 to September 2017, the REMIND group conducted a prospective n...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14944

    authors: Auzolle C,Nancey S,Tran-Minh ML,Buisson A,Pariente B,Stefanescu C,Fumery M,Marteau P,Treton X,Hammoudi N,REMIND Study Group Investigators.,Jouven X,Seksik P,Allez M

    更新日期:2018-11-01 00:00:00

  • Review article: the burden of illness of non-cardiac chest pain.

    abstract:BACKGROUND:Non-cardiac chest pain is a common condition affecting approximately one-quarter of the population during their lifetime, but the long-term economic costs of non-cardiac chest pain are poorly defined. METHODS:A MEDLINE and Current Contents search was performed from 1991 to 2002 using specific keywords. All ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01296.x

    authors: Eslick GD,Coulshed DS,Talley NJ

    更新日期:2002-07-01 00:00:00

  • Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages.

    abstract:BACKGROUND:Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD. Carriers have been reported to better respond to lifestyle modification. AIM:To investig...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13232

    authors: Mangge H,Baumgartner BG,Zelzer S,Prüller F,Schnedl WJ,Reininghaus EZ,Haybaeck J,Lackner C,Stauber R,Aigner E,Weghuber D

    更新日期:2015-07-01 00:00:00

  • Development of a clinical hepatic encephalopathy staging scale.

    abstract:AIM:To develop a scale to assess the severity of hepatic encephalopathy using simple dichotomic items. METHODS:A list of 48 items was created by selecting items that are simple to recognize and categorize; it was applied to thirty-six cirrhotic in-patients with episodic encephalopathy, in addition to the adapted-West-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03394.x

    authors: Ortiz M,Córdoba J,Doval E,Jacas C,Pujadas F,Esteban R,Guardia J

    更新日期:2007-09-15 00:00:00

  • Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.

    abstract:BACKGROUND:Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. AIM:To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. METHODS:Eleven patients (10%) diagnosed with fulminant...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02894.x

    authors: Miyake Y,Iwasaki Y,Terada R,Onishi T,Okamoto R,Sakai N,Sakaguchi K,Shiratori Y

    更新日期:2006-05-01 00:00:00

  • Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

    abstract:AIM:To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study. METHODS:Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01292.x

    authors: Warrington S,Baisley K,Boyce M,Tejura B,Morocutti A,Miller N

    更新日期:2002-07-01 00:00:00

  • Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

    abstract:BACKGROUND:The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available. AIM:To compare the efficacy of terlipressin plus albumin vs. placebo plus albumin in p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.14052

    authors: Sanyal AJ,Boyer TD,Frederick RT,Wong F,Rossaro L,Araya V,Vargas HE,Reddy KR,Pappas SC,Teuber P,Escalante S,Jamil K

    更新日期:2017-06-01 00:00:00

  • Review article: liver transplantation for the pulmonary disorders of portal hypertension.

    abstract:BACKGROUND:Liver transplantation is potentially a life-saving therapeutic intervention for patients with portopulmonary hypertension and hepatopulmonary syndrome. However, due to limited data, listing criteria for patients with these conditions have not been clearly established. Indeed, this has led some to speculate t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12140

    authors: Houlihan DD,Holt A,Elliot C,Ferguson JW

    更新日期:2013-01-01 00:00:00